Preventing Recurrent Clostridioides difficile Infections with Fecal Microbiota-Based Therapies : Episode 14
ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
EP: 1.Epidemiology of C. difficile Infections in the US
EP: 2.Recurrence of C. Difficile Infections
EP: 3.Risk Factors for C. difficile Infections
EP: 4.Patients at Risk for Recurrent C. difficile Infections and the Role of Environmental Factors
EP: 5.Diagnostic Tests for C. difficile Infections
EP: 6.Treatment Guidelines for C. difficile Infection
EP: 7.Factors Contributing to C. difficile Infection Recurrence
EP: 8.Managing C. difficile Infections in the Clinic
EP: 9.Contribution of Unnecessary and Prolonged Antibiotic Use to Recurrent C. difficile Infections
EP: 10.Fecal Microbiota Transplantation for C. difficile Infections
EP: 11.Recent Fecal Microbiota Transplant Approvals for C. difficile Infections
EP: 12.Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice
EP: 13.Data on Fecal Microbiota, Live-JSLM (RBL) for C. difficile Infections
Now Viewing
EP: 14.ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
EP: 15.Safety of Fecal Microbiota Options and Transfer of Food-Borne Allergens
EP: 16.Utilization of Fecal Microbiota Transplant Products in Clinical Practice
Video content above is prompted by the following:
- Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
- Comparing the two clinical trials, what were some significant differences between them?
Recent Videos
Related Content
